Sign in to view content

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study

Charles C Wykoff, MD, PhD, FASRS

Video
Published 2024

Related

Clinical Feasibility of Ultra-rapid, Non-pharmacologic Anesthesia for Intravitreal Injection in Patients Receiving Anti-VEGF
Cagri G Besirli, MD, PhD, FASRS
Updates from the Field
2018
Retinal Nonperfusion and Anti-VEGF Therapy in Diabetic Retinopathy: What We Know and What We Don’t Know
Dante Joseph Pieramici, MD
Updates from the Field
2017
Effect of 6 month anti-VEGF treatment for proliferative diabetic retinopathy on the quantitative metrics of the retinal microvasculature on OCTA
Quan V. Hoang, MD, PhD
On Demand Cases, Courses, and Papers
2019

Category: AMD-Neovascular

See more